Key Points
- Major shareholder Jorey Chernett purchased 20,000 shares of Oncology Institute on April 9 at $3.10, bringing his direct stake to 10,499,358 shares (≈$32.55M); this follows a recent buying spree of roughly 568,985 shares since March 13, costing about $1.76M in total.
- TOI trades with a market cap of $326.17M and a 52-week range of $1.80–$4.88, and analysts hold a consensus “Moderate Buy” with an average price target of $7 (several firms recently reaffirmed or raised buy ratings and targets to $5–$8).
-logo-1200x675.png?v=20220303080937)
The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) major shareholder Jorey Chernett acquired 20,000 shares of the company's stock in a transaction on Thursday, April 9th. The shares were bought at an average price of $3.10 per share, with a total value of $62,000.00. Following the completion of the purchase, the insider directly owned 10,499,358 shares of the company's stock, valued at approximately $32,548,009.80. This represents a 0.19% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Jorey Chernett also recently made the following trade(s):
- On Tuesday, March 24th, Jorey Chernett acquired 125,000 shares of Oncology Institute stock. The shares were bought at an average price of $3.11 per share, with a total value of $388,750.00.
- On Friday, March 20th, Jorey Chernett acquired 25,000 shares of Oncology Institute stock. The shares were bought at an average price of $3.35 per share, with a total value of $83,750.00.
- On Tuesday, March 17th, Jorey Chernett acquired 75,000 shares of Oncology Institute stock. The shares were bought at an average price of $3.42 per share, with a total value of $256,500.00.
- On Monday, March 16th, Jorey Chernett acquired 60,985 shares of Oncology Institute stock. The shares were bought at an average price of $3.29 per share, with a total value of $200,640.65.
- On Friday, March 13th, Jorey Chernett acquired 263,000 shares of Oncology Institute stock. The shares were bought at an average price of $2.92 per share, with a total value of $767,960.00.
Oncology Institute Stock Performance
Shares of TOI stock opened at $3.30 on Tuesday. The stock's fifty day moving average is $2.90 and its 200-day moving average is $3.38. The stock has a market capitalization of $326.17 million, a PE ratio of -5.89 and a beta of 0.17. The Oncology Institute, Inc. has a 52 week low of $1.80 and a 52 week high of $4.88.
Oncology Institute (NASDAQ:TOI - Get Free Report) last announced its earnings results on Thursday, March 12th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The business had revenue of $141.96 million for the quarter, compared to the consensus estimate of $139.78 million.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on TOI. Needham & Company LLC restated a "buy" rating and set a $5.00 target price on shares of Oncology Institute in a report on Monday, March 9th. B. Riley Financial increased their target price on Oncology Institute from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Friday, March 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Oncology Institute in a report on Wednesday, January 21st. Finally, BTIG Research restated a "buy" rating and set a $7.00 target price on shares of Oncology Institute in a report on Monday, March 9th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $7.00.
Check Out Our Latest Stock Analysis on Oncology Institute
Hedge Funds Weigh In On Oncology Institute
Hedge funds have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new position in Oncology Institute in the fourth quarter valued at about $31,000. Pekin Hardy Strauss Inc. bought a new position in Oncology Institute in the fourth quarter valued at about $36,000. R Squared Ltd bought a new position in Oncology Institute in the fourth quarter valued at about $41,000. Prelude Capital Management LLC bought a new position in Oncology Institute in the third quarter valued at about $41,000. Finally, BNP Paribas Financial Markets boosted its holdings in Oncology Institute by 141.0% in the third quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company's stock valued at $42,000 after acquiring an additional 7,091 shares during the last quarter. Institutional investors own 36.86% of the company's stock.
About Oncology Institute
(
Get Free Report)
The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
